Utter nonsense! There was a definite coordinated attack on this stock all lined up ready to go and began 10 seconds after the data was made public. Good data, no less. There is no way that retail investors and daytraders could achieve what was done on Wednesday afternoon. You are living in Fantasyland, JQ.
Really, I have to agree with frrol here. Holly is being DUPED by the negative bash campaign. Overreacting to the negative bias and throwing Missling under the bus. She may be smart but obviously not educated enough in the biosciences to understand that the results here were good.
darullo, the only reason my call regarding AVXL - last day to get in cheap - did not pan out is because of the coordinated attack on this stock. The favorable data results should have gotten us at least to $9, where as part of my usual strategy I would have traded 10-15% of my total holdings and then bought back in on a pullback. Unfortunately when you have powerful attacks like we had this past week, normal expectations go out the window. As for my strategy, it has served me well over the years, but frankly has not worked so well with my 2 primary biotechs over the last 11 months.
At their current price points both AVXL and NVIV are good buys if you are an investor and not a day trader.
Hey sparky, you wouldn't know the first thing about investing in biotechs. I don't do much trading. Those tickers down ~50% represent an excellent buying opportunity. Most normal gainfully employed Americans do not have time to play "video games" with stock tickers. We see future value and then buy and hold and trade around the core. The trades made around the core are at highs, so even my paper loss red share lots do not truly represent my cost. Do you finally get it?
Hey chem, probably true (unless we have a surprise next week), but you might want to add that toward the end of those couple months we should be seeing a nice rise in anticipation of the next news. Than news will have a different flavor. I am quite certain the PK/PD data will be unambiguously favorable. And if cognitive measures hold stable through the next milepost then A-273 will have done what NO OTHER Alzheimer drug candidate has ever done before. Albeit the small sample size, I'd bet my house just on the indicators thus far, that we have a better drug here than Aricept.
This drug has multiple modes of action. Its S1 agonist action works on hindering and stabilizing the earlier cascades of the disease, while the mixed muscarinic agonist activity replaces what Aricept attempts to do on the symptomatic side.
Appreciate your sympathy envy. Fortunately it is only a paper loss...just like here. I've got green share lots and red share lots...just like here.
Traders might advise to sell all the green share lots. But I am for the most part a buy and hold investor who skims around 10-15% of holdings on sustained highs. Unfortunately for NVIV its been a year since we've had a stable high. INSPIRE is going well in terms of its success, but it is taking much longer than most people have anticipated and we are stuck in this suppressed price range until something big happens.
Hey envy. If I had sold 6000 shares of NVIV the day before Perrin's last secret "public" offering became known and then bought AVXL that same day. And then waited a few months and sold those shares of AVXL, I would have had enough to buy a new Tesla.
And concurred elsewhere. Shorts get exposed but after they inflict "damage"
The word is in quotes because we have an opportunity to buy more shares at a lower price point.
Looking forward to some qualified analyst putting out an interpretation because the facts are the facts. The data that they presented was quite positive.
Bump for the troll that claims the company backpedaled. And an added message. I have never promoted the company's study and I've understood the nature of it for more than a year (since my exposure to this investment). Yes it is still early. It is not weak and it is not unimpressive. The data is very positive for this stage of the process and bodes well for future trial.
Wow, interesting. I never thought about it that way. I'd be very disappointed in the professor if that were so. I've always been nice to him too.